Metastatic Castration-Resistant Prostate Cancer Market Size to Grow at a CAGR of 5.44% during 2024-2034, Impelled by Advancements in Early Detection

Metastatic Castration-Resistant Prostate Cancer Market Outlook 2024-2034:

The metastatic castration-resistant prostate cancer market size is expected to exhibit a CAGR of 5.44% during 2024-2034. The market is driven by the emerging popularity of targeted therapies, such as enzalutamide, abiraterone acetate, apalutamide, etc., that can block specific pathways involved in the proliferation and progression of tumor growth.

Advances in Early Detection and Diagnostic Technologies: Driving the Metastatic Castration-Resistant Prostate Cancer Market 

Advances in early detection and diagnostic technologies are playing a pivotal role in driving the market for metastatic castration-resistant prostate cancer (mCRPC). One of the most important advancements is the development of liquid biopsy technologies, which detect circulating tumor DNA (ctDNA) and circulating tumor cells (CTCs) in blood samples. These non-invasive tests offer several advantages over traditional biopsies, including the ability to monitor disease progression, assess treatment response, and identify mutations associated with resistance to therapies. Liquid biopsies are becoming essential for assessing genomic alterations in mCRPC, helping clinicians guide precision medicine and select the most appropriate targeted therapies. Additionally, the introduction of PSMA (Prostate-Specific Membrane Antigen) imaging has revolutionized the detection and staging of mCRPC. PSMA PET scans, which use radiolabeled tracers to target PSMA on prostate cancer cells, allow for more precise localization of metastatic lesions compared to conventional imaging techniques like CT and MRI. This improved sensitivity and specificity in detecting metastases help clinicians monitor disease spread, predict treatment outcomes, and evaluate the efficacy of therapies like PSMA-targeted radioligand therapy. Together, these advancements in molecular diagnostics, genetic profiling, and imaging technologies are driving early diagnosis, improving personalized treatment approaches, and expanding the mCRPC market by offering more effective and tailored solutions for patients, ultimately enhancing survival rates and quality of life.

Development of Novel Therapies and Pharmacological Treatments: Contributing to Market Expansion

The development of novel therapies and pharmacological treatments is a key driver in the expansion of the metastatic castration-resistant prostate cancer (mCRPC) market. One of the most notable advances in treatment is the emergence of second-generation androgen receptor inhibitors (ARIs), such as enzalutamide and abiraterone acetate. These drugs work by further blocking the androgen receptor signaling pathway, which is critical for prostate cancer cell growth. Unlike earlier therapies, second-generation ARIs can suppress androgen receptor function even when the cancer cells have become resistant to traditional androgen deprivation therapy. Their ability to extend survival and improve quality of life in mCRPC patients has made them mainstays in the treatment arsenal. In addition to ARIs, chemotherapy agents like docetaxel and cabazitaxel continue to play an important role in mCRPC management. However, newer targeted therapies and immunotherapies are rapidly gaining attention. PARP inhibitors, such as olaparib, are showing promise in treating mCRPC with specific BRCA mutations and other DNA repair defects, offering a more personalized treatment approach. Additionally, immune checkpoint inhibitors and PSMA-targeted therapies are offering new mechanisms of action, targeting the immune system or specific markers on cancer cells, leading to improved treatment efficacy. Furthermore, radiopharmaceuticals, like Radium-223 and the experimental PSMA-targeted radioligand therapies, are showing potential for selectively delivering radiation to metastatic prostate cancer cells, providing localized and potent treatment with minimal damage to surrounding healthy tissues. These advancements in targeted treatments, combined with new combination therapies, are revolutionizing mCRPC care, expanding the market by offering more effective and individualized therapeutic options, and ultimately improving survival rates for patients.

Marketed Therapies in Metastatic Castration-Resistant Prostate Cancer Market

Pluvicto (Lutetium-177 vipivotide tetraxetan): Advanced Accelerator Applications 

Pluvicto (Lutetium-177 vipivotide tetraxetan) is a precision cancer treatment that combines a targeted chemical and a radioactive particle to treat metastatic castration-resistant prostate cancer. Lutetium Lu-177 vipivotide tetraxetan combines lutetium Lu-177, a radionuclide, with an active pharmacological moiety that binds to prostate‐specific membrane antigen (PSMA). Once delivered, lutetium Lu 177 vipivotide tetraxetan binds to cells that express PSMA. The beta-minus emission from lutetium Lu-177 distributes radiation to PSMA-expressing cells as well as surrounding cells, inducing DNA damage that can lead to cell death.

Lynparza (Olaparib): AstraZeneca

Lynparza (Olaparib) is indicated to treat adult patients with deleterious or suspected detrimental germline or somatic homologous recombination repair (HRR) gene-mutated metastatic castration-resistant prostate cancer. Olaparib is a poly(ADP-ribose) polymerases (PARPs) inhibitor that selectively inhibits NAD+ at the catalytic region of PARP1 and PARP2. Olaparib inhibits the base excision repair pathway, causing an accumulation of unrepaired single-strand breaks that lead to the creation of double-strand breaks, the most damaging type of DNA damage. While BRCA-dependent homologous recombination may repair double-strand breaks in normal cells, it fails in cells with BRCA1/2 mutations, such as some cancer cells. Inhibition of PARP in cancer cells with BRCA mutations causes genomic instability and apoptosis.

Rubraca (Rucaparib): Clovis Oncology

Rubraca (Rucaparib) is indicated for the treatment of adult patients with a deleterious BRCA mutation (germline and/or somatic)-associated metastatic castration-resistant prostate cancer who have been treated with androgen receptor-directed therapy and a taxane-based chemotherapy. Rucaparib inhibits PARP1, PARP2, and PARP3. Inhibiting PARP traps the enzyme on damaged DNA, stopping the repair process and generating hazardous PARP-DNA complexes. Other DNA repair processes, such as error-prone nonhomologous end joining (NHEJ) or alternative end-joining pathways, can be activated, resulting in mutations or chromosomal changes. Further DNA damage can cause cancer cell apoptosis and death.

Zytiga (Abiraterone acetate): Johnson & Johnson 

Zytiga (Abiraterone acetate) is an antiandrogen used in the treatment of metastatic castration-resistant prostate cancer and metastatic high-risk castration-sensitive prostate cancer. Zytiga is an orally administered prodrug that is transformed into abiraterone in the body. Abiraterone inhibits CYP17, an enzyme that produces androgens such as testosterone and dihydrotestosterone, both of which are needed for prostate cancer growth.

Provenge (Sipuleucel-T): Dendreon Corporation

Provenge (Sipuleucel-T) is an autologous cellular immunotherapy used to treat asymptomatic or mildly symptomatic metastatic castrate-resistant (hormone refractory) prostate cancer. This therapeutic vaccination is intended to trigger an immune response to prostate cancer cells by targeting prostate acid phosphatase (PAP), a tissue antigen found in prostate cancer cells. The therapeutic goal is to create PAP-specific T lymphocytes that can recognize and kill prostate cancer cells that express PAP.

Emerging Therapies in Metastatic Castration-Resistant Prostate Cancer Market

ZEN003694: Zenith Epigenetics 

ZEN003694 is an orally bioavailable, second-generation, effective bromodomain extra-terminal inhibitor (BETi) with activity in androgen signaling inhibitor-resistant models. ZEN003694 works by inhibiting a group of proteins known as bromodomain and extra-terminal proteins, which may reduce the effect of nuclear receptor-binding SET domain protein 3 (NSD3) on tumor growth. Blocking these proteins may reduce or prevent tumor growth.

ONCT-534: Oncternal Therapeutics

ONCT-534 is an experimental dual-action androgen receptor inhibitor (DAARI) that has shown preclinical effectiveness in prostate cancer models against both unmutated androgen receptor (AR) and different types of AR mutation and aberration. It is an effective therapy for patients with mCRPC who have unmet medical needs due to resistance to androgen receptor pathway inhibitors, such as those with AR amplification, AR ligand binding domain (LBD) mutations, or AR LBD loss splice variants. It was tested in Study ONCT-534-101 (NCT05917470) to treat individuals with mCRPC who are resistant to existing AR pathway inhibitors.

Acapatamab: Amgen

Acapatamab is a half-life extended (HLE) BiTE immune-oncology medication that targets prostate-specific membrane antigen (PSMA)-expressing cancer cells being investigated in prostate cancer.

Acapatamab, which binds to both PSMA on tumor cells and CD3 on T cells, is intended to activate patients' T cells to combat cancer. In phase I, a first-in-human study in patients with metastatic castration-resistant prostate cancer, acapatamab showed a manageable safety profile and promising efficacy as monotherapy.

TmPSMA-02: Tmunity Therapeutics

TmPSMA-02 is a chimeric antigen receptor (CAR) T-cell treatment that functions by binding to and destroying PSMA-expressing prostate cancer cells. TmPSMA-02 CAR T cells are genetically modified T cells derived from a patient's blood and cultured in a laboratory. T cells are then injected into the patient to treat malignancy. The CAR receptor on T cells interacts with PSMA, a protein found in prostate cancer cells. This enables the T lymphocytes to recognize and eliminate cancer cells.

REGN5678: Regeneron Pharmaceuticals

REGN5678 is a human IgG4-based, costimulatory bispecific antibody that targets prostate tumors by bridging prostate-specific membrane antigen-expressing tumor cells with the costimulatory receptor, cluster of differentiation 28 (CD28) on T-cells. This leads to increased T-cell receptor-CD3 complex-mediated T-cell activation within the tumor by activating CD28 signaling. By engaging previously activated T-cells that express CD28, REGN5678 may exhibit less toxicity than CD3-directed bi-specifics.

Detailed list of emerging therapies in Metastatic Castration-Resistant Prostate Cancer is provided in the final report.

Leading Companies in the Metastatic Castration-Resistant Prostate Cancer Market:

The market research report by IMARC encompasses a comprehensive analysis of the competitive landscape in the market. Across the global metastatic castration-resistant prostate cancer market, several leading companies are at the forefront of developing integrated platforms to enhance the management of metastatic castration-resistant prostate cancer. Some of the major players include Advanced Accelerator Applications, AstraZeneca, and Clovis Oncology. These companies are driving innovation in the metastatic castration-resistant prostate cancer market through continuous research and diagnostic tools, and expanding their product offerings to meet the growing demand for the illness.

​In September 2024, Foundation Medicine, Inc. announced that it had received approval from the U.S. FDA for FoundationOneCDx and FoundationOneLiquid CDx to be used as companion diagnostics for AstraZeneca's and Merck's Lynparza (olaparib) in combination with abiraterone and prednisone or prednisolone for the treatment of adult patients with deleterious or suspected deleterious BRCA-mutated metastatic castration-resistant prostate cancer.

In October 2023, Novartis released data from the Phase III PSMAfore trial at the 2023 European Society for Medical Oncology (ESMO) Congress. The data presented at the Presidential Symposium demonstrated that Pluvicto (lutetium (177Lu) vipivotide tetraxetan) fulfilled its primary endpoint with a clinically meaningful and statistically significant benefit in radiographic progression-free survival in patients with prostate-specific membrane antigen (PSMA)-positive metastatic castration-resistant prostate cancer after treatment with androgen receptor pathway inhibitor (ARPI) therapy, compared to a change in ARPI.

Key Players in Metastatic Castration-Resistant Prostate Cancer Market:

The key players in the Metastatic Castration-Resistant Prostate Cancer market who are in different phases of developing different therapies are Advanced Accelerator Applications, AstraZeneca, Clovis Oncology, Johnson & Johnson, Dendreon Corporation, Zenith Epigenetics, Oncternal Therapeutics, Amgen, Tmunity Therapeutics, Regeneron Pharmaceuticals, and Others.

Regional Analysis:

The major markets for metastatic castration-resistant prostate cancer include the United States, Germany, France, the United Kingdom, Italy, Spain, and Japan. According to projections by IMARC, the United States has the largest patient pool for metastatic castration-resistant prostate cancer while also representing the biggest market for its treatment. This can be attributed to the approval and utilization of radiopharmaceuticals like Radium-223 for metastases, which has expanded treatment options, addressing the unmet needs of patients with advanced disease.

Moreover, the increasing adoption of targeted therapies, including PARP inhibitors and PSMA-targeted therapies, is propelling market growth. These treatments, which provide more personalized and effective options, are particularly significant for patients with specific genetic mutations or biomarkers.

Besides this, the increasing awareness and early detection of prostate cancer, facilitated by improved diagnostic technologies and screening methods, is bolstering the market growth. Early-stage detection allows for better management and timely transition to advanced treatments in patients who develop mCRPC​.

Recent Developments in Metastatic Castration-Resistant Prostate Cancer Market:

• In October 2024, Oncternal Therapeutics, Inc. announced updated findings from its Phase 1/2 Study of ONCT-534 for the treatment of patients with relapsed or refractory metastatic castration-resistant prostate cancer.
   

Key information covered in the report.

• Base Year: 2023
• Historical Period: 2018-2023
• Market Forecast: 2024-2034
   

Countries Covered

• United States
• Germany
• France
• United Kingdom
• Italy
• Spain
• Japan
   

 Analysis Covered Across Each Country

• Historical, current, and future epidemiology scenario
• Historical, current, and future performance of the metastatic castration-resistant prostate cancer market
• Historical, current, and future performance of various therapeutic categories in the market
• Sales of various drugs across the metastatic castration-resistant prostate cancer market
• Reimbursement scenario in the market
• In-market and pipeline drugs
   

Competitive Landscape:

This report offers a comprehensive analysis of current metastatic castration-resistant prostate cancer marketed drugs and late-stage pipeline drugs.

In-Market Drugs

• Drug Overview
• Mechanism of Action
• Regulatory Status
• Clinical Trial Results
• Drug Uptake and Market Performance
   

 Late-Stage Pipeline Drugs

• Drug Overview
• Mechanism of Action
• Regulatory Status
• Clinical Trial Results
• Drug Uptake and Market Performance
   

About Us:

IMARC Group is a global management consulting firm that helps the world’s most ambitious changemakers to create a lasting impact. Across the six major continents and 100+ countries, we work alongside our business partners as one team with a common ambition to achieve unparallelled results, gain a competitive edge, and transform industries. IMARC Group excels in understanding its clients’ business priorities and delivering tailored solutions that drive meaningful outcomes. Our client base spans over 3,000 organizations in the private, public, and social sectors, ranging from high-growth startups to Fortune 500 companies.

Contact US

IMARC Group
134 N 4th St. Brooklyn, NY 11249, USA
Email: Sales@imarcgroup.com
Tel No:(D) +91 120 433 0800
Phone Number: - +1 631 791 1145, +91-120-433-0800